Starna Therapeutics focuses on developing innovative RNA-based therapeutics with a particular emphasis on extrahepatic (beyond the liver) targeted delivery technologies. Established in August 2021, the company aims to address unmet clinical needs by leveraging its expertise in nucleic acid drug discovery, delivery technologies, and formulation development. The core team comprises professionals from renowned pharmaceutical companies, universities, and research institutions, which enhances their capability to tackle the challenges associated with RNA drug development. Starna has built a comprehensive industrial chain around chemical, mRNA, and lipid nanoparticle (LNP) formulations, positioning itself as a leader in the RNA therapeutics space.

The company has developed a specialized LNP drug delivery system designed for extrahepatic targeting, which enhances the stability and bioavailability of RNA drugs. Their approach includes the creation of tissue-specific LNPs (tsLNPs) through a vast library of lipid molecules, allowing for precise drug delivery to various organs such as muscle, pancreas, lung, spleen, and liver. Additionally, Starna is advancing cell-selective LNPs (csLNPs) by coupling ligands like antibodies to LNPs, enabling targeted delivery to specific subcellular types. This technology shows significant promise for applications in in-vivo cell therapies, further expanding the potential of RNA-based treatments.

China

Starna Therapeutics focuses on extrahepatic targeted delivery technology and is committed to developing innovative drugs with RNA as the core to solve unmet clinical needs. The core team comes from well-known pharmaceutical companies, universities and research institutes. The team has profound capabilities in nucleic acid drug discovery, delivery technology and formulation development.

Starna Therapeutics

Company Details